ArticleVeterinary clinical pathology2025
Comparison of Hemostatic Activity in Canine Leukoreduced Cryoprecipitate, Cryopoor Plasma, and Fresh Plasma.
Article in Veterinary clinical pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundTo date, no studies have reported the evaluation of hemostatic activity in canine leukoreduced cryoprecipitate (LR-CRYO) and leukoreduced cryopoor plasma (LR-CPP).
objectivesWe aimed to compare the hemostatic activity of LR-CRYO and LR-CPP to leukoreduced fresh plasma (LR-FP) and to evaluate the preservation of LR-CRYO by refrigeration and refreezing after thawing.
methodsFour hundred fifty milliliters of fresh blood was collected from ten donor dogs, leukoreduced, and separated into LR-FP, then frozen (-20°C) to obtain leukoreduced fresh frozen plasma (LR-FFP). LR-FFP was further separated into LR-CRYO and LR-CPP. LR-CRYO was frozen, thawed, and divided into two bags, one refrigerated for 24 h and one refrozen for 7 days. Factor VIII (FVIII) and X (FX) activity, prothrombin time, activated partial thromboplastin time, antithrombin III (ATIII) activity (ATA), total protein, albumin, fibrinogen, and D-dimer concentration, and von Willebrand Factor (vWF) activity were measured in LR-FP, LR-CRYO, LR-CPP, refrigerated, and refrozen LR-CRYO.
resultsFVIII activity was higher in LR-CRYO (p = 0.0001) versus LR-FP. vWF activity (p < 0.0001) and fibrinogen concentration (p = 0.0012) were lower in LR-CPP versus LR-FP. FX activity was higher in LR-CPP (p < 0.0001) and LR-FP (p = 0.0002) versus LR-CRYO, and albumin concentration was higher in LR-CPP versus LR-FP (p < 0.0001) and LR-CRYO (p < 0.0001). No statistically significant difference was found in refrigerated or refrozen LR-CRYO as compared with LR-CRYO, excluding ATA, which was lower (p = 0.0062) in refrigerated LR-CRYO.
conclusionsBecause the concentration of FVIII is higher in LR-CRYO than in LR-FP, LR-CRYO is a possible component therapy when this factor is deficient. Since no statistically significant difference was found in refrozen LR-CRYO as compared with LR-CRYO, LR-CRYO can be frozen after thawing for reuse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.